

16 January 2023

Therapeutic Goods Administration
Via the TGA consultation portal

To whom it may concern,

Re: Proposed reforms to the regulation of nicotine vaping products

Medicines Australia welcomes consultation on potential reforms to the regulation of nicotine vaping products (NVPs) in Australia.

Effective regulation of NVPs is important to the health of Australians and Medicines Australia supports the Therapeutic Goods Administration's (TGA) work on this public health matter.

Funding for important public health regulatory measures such as this should be funded by the Federal Government and should not be funded through TGA revenue raising measures such as existing cost-recovery models.

The Australian Government's cost recovery guidelines are clear that industry fees and charges should accurately reflect the fee for services provided directly to a specific individual or organisation¹.

Medicines Australia recognises the significant pressures the TGA is under to deliver a first-class regulatory framework. The TGA's role in supporting public health through regulation and other measures is critical.

A Federal Budget in May 2023 is an opportune time to repair the TGA's budget and we wish the TGA well as it works with the Federal Government on this matter. It is in Australia's interests that the TGA is funded, commensurate with other similar national regulatory agencies, in a sustainable manner so it remains a globally respected regulator.

To discuss these issues further, please contact Eric Johnsson (Senior Manager, Policy Eric.Johnsson@medicinesaustralia.com.au).

Yours sincerely,



Elizabeth de Somer
CEO
Medicines Australia

¹ <https://www.finance.gov.au/publications/resource-management-guides/australian-government-cost-recovery-guidelines-rmg-304>